Heska to Present at Canaccord Genuity 38th Annual Growth Conference on August 8th

Wednesday, August 1, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

LOVELAND, Colo., Aug 1, 2018 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider

of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson, Heska's President & Chief Executive Officer will be presenting in a Fireside Chat at the Canaccord Genuity 38th Annual Growth Conference
at 2:30 p.m. ET on Wednesday, August 8, 2018.

The conference will be held August 8-9, 2018 at the InterContinental Boston Hotel in Boston, MA. A copy of the presentation can be found on Heska's website at https://ir.heska.com/event/presentation/.  Management will be available during the day on August 8th for one-one-one meetings.  To schedule a one-on-one meeting with management, please contact Brett Maas at Hayden IR.

About Heska

Heska Corporation (NASDAQ: HSKA - News) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products. Heska's business is composed of Core Companion Animal Health ("CCA") and Other Vaccines, Pharmaceuticals and Products ("OVP"). CCA includes, primarily for canine and feline use, point of care laboratory testing instruments and supplies under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP includes, primarily for herd animal health, private label vaccine and pharmaceutical production under third party agreements and channels. For further information on Heska and its products, visit www.heska.com.

 

Cision View original content:http://www.prnewswire.com/news-releases/heska-to-present-at-canaccord-genuity-38th-annual-growth-conference-on-august-8th-300689771.html

SOURCE Heska Corporation



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store